Roche Holding AG announced plans to acquire PathAI for up to $1.05 billion, marking a significant investment in artificial intelligence-powered diagnostic tools by the Swiss pharmaceutical and diagnostics giant.

The acquisition is designed to strengthen Roche's diagnostics division by integrating PathAI's artificial intelligence capabilities into its existing portfolio. PathAI specializes in machine learning technologies for pathology and medical diagnostics, offering AI-powered tools that assist in analyzing tissue samples and medical imaging.

Roche expects the deal to accelerate the development of clinical therapies by improving diagnostic accuracy and efficiency. The integration of PathAI's technology could enhance Roche's ability to support drug development processes and provide more precise diagnostic solutions to healthcare providers.

The transaction represents Roche's continued focus on expanding its presence in the growing digital health and AI diagnostics market. As healthcare systems increasingly adopt artificial intelligence tools to improve patient outcomes and operational efficiency, pharmaceutical companies are investing heavily in AI capabilities to maintain competitive advantages.

The deal's structure includes potential milestone payments that could bring the total value to $1.05 billion, though specific terms and closing conditions were not immediately disclosed. The acquisition is expected to complement Roche's existing diagnostics business, which already serves healthcare providers worldwide with laboratory testing equipment and services.